Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer
Launched by RIGSHOSPITALET, DENMARK · Mar 30, 2015
Trial Information
Current as of October 13, 2025
Completed
Keywords
ClinConnect Summary
INTRODUCTION More than 30.000 individuals are living with a colorectal cancer (CRC) diagnosis in Denmark today. Due to marked advances in surgical and medical treatment, as well as novel screening programs, this number is expected to increase over the coming years. Numerous studies have shown that physical activity is inversely associated with colorectal cancer risk. A meta-analysis of 52 studies found that regular participation in physical activity reduced disease risk by 24% (HR: 0.76 , 95%Confidence Interval \[95%CI\]: 0.72 - 0.81). Recent evidence furthermore shows that physical activit...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a verified stage I-III CRC diagnosis who has
- • All surgical and oncological treatments must be terminated
- Exclusion Criteria:
- • Any major surgical procedure planned within 6 months after inclusion
- • Pregnancy
- • Ongoing treatment for any known current malignancy
- • Performance status \> 1
- • Inability to read and understand Danish
- • Physically active for more than 150 minutes (moderate intensity) per week thus adhering to the current recommendations
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Denmark
Hvidovre, Denmark
Patients applied
Trial Officials
Jesper F Christensen, PhD
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials